Cinclus Pharma Holding Ab · OMXSTO:CINPHA
Cinclus Pharma Holding Ab — Q2 2025 Earnings Presentation
13 slides from Cinclus Pharma Holding Ab's earnings presentation, Aug 20, 2025
Slide 1: Cinclus Pharma Q2 Report 2025
Cinclus Pharma Q2 Report 2025 Webcast Aug 20, 2025, 10:00 CET Presenters: Christer Ahlberg, CEO Maria Engström, CFO Jesper Wiklund Head of Corporate and Business Development 1
Slide 2: Disclaimer
Disclaimer IMPORTANT: You must read the following before continuing. The following applies to this and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the “Order”), a “qualified document, the oral presentation of the information in this document by Cinclus Pharma Holding investors” fal
Slide 3: Linaprazan glurate starting Phase III program - poised to enter a large market
Linaprazan glurate starting Phase III program - poised to enter a large market HQ: Stockholm, Sweden Linaprazan glurate Phase III start Next generation PCAB. underpinned by Potential to become best in class with unique 24h acid control. strong Phase II study PCABs first innovative MoA 1) in Phase II
Slide 4: 24 hr acid control is linearly correlated to healing
24 hr acid control is linearly correlated to healing Mean percentage of time the intragastric pH>4 predicts healing rate 100 R2 Linear = 0.743 90 80 70 The longer pH Healing rates 4 weeks 60 is maintained 50 above 4, the higher healing 40 rates of 30 esophagitis 20 10 0 0 20 40 60 80 100 Percent 24h
Slide 5: Time pH>4 correlation with healing aligns with vonoprazan US phase III study
Time pH>4 correlation with healing is in alignment with healing rates in vonoprazan US phase III study Mean percentage of time the intragastric pH>4 predicts healing rate 100 R2 Linear = 0.743 90 Linaprazan glurate 50mg bid 80 for phjase 3 70 pH>4 Erosive GERD Healing Vonoprazan 20mg 60 96% pH>4 LA
Slide 6: Summary of key events
Summary of key events • Entered a strategic alliance and license agreement with Zentiva for the commercialization and manufacturing of linaprazan glurate in Europe. The deal is valued at up to EUR 220 million, including upfront, regulatory, and commercial milestone payments and Tiered royalties on E
Slide 7: Strategic partnership with Zentiva for commercialization and manufacturing of linaprazan glurate in Europe
Strategic partnership with Zentiva for commercialization and manufacturing of linaprazan glurate in Europe This strategic alliance with Zentiva: • Marks a significant inflection point for Cinclus Pharma and for linaprazan glurate • Covers everything necessary to bring linaprazan glurate to the marke
Slide 8: Zentiva partnership: commercialization and manufacturing of linaprazan glurate in Europe
Zentiva partnership: commercialization and manufacturing of linaprazan glurate in Europe • Formerly a part of Sanofi, it was divested in 2018 • Recognized for its growing portfolio of established and innovative treatments, Zentiva specializes in gastrointestinal and metabolic disorders, among other
Slide 9: Financials
Financials
Slide 10: Quarter by quarter 2023-2025
Quarter by quarter 2023-2025 R&D Expenses last 8 quarters (excl. one-time expenses) (SEK million) Q2-25 Q1-25 Q4-24 Q3-24 Q2-24 Q1-24 Q4-23 Q3-23 (SEK million) 70 100% Cash end of period 589 524 567 644 685 52 88 151 90% Cash flow 65 -43 -77 -41 633 -36 -63 42 60 80% Revenues 34 – 5 – – – – – 50 70%
Slide 11: Financial overview YoY
Financial overview YoY SEKm Q2-25 Q2-24 YoY Jan-Dec-24 • Net sales (SEKm +34,1) Net sales 34,1 – 34,1 4,6 Revenues from the Zentiva Europe out-licensing deal. Of the €13M upfront, €3.8M was booked in June upon license grant; the remainder will be recognized over the Phase 3 study period. G&A -27,2 -
Slide 12: Largest shareholders end of June 2025
Largest shareholders end of June 2025 Number of shares Share (%) Trill Impact Ventures 3 721 221 7,9% Founders: Fjärde AP-fonden 3 700 000 7,8% Movestic Livförsäkring AB 2 339 052 4,9% Linc AB 2 318 322 4,9% - Peter Unge Peter Unge via company 2 090 015 4,4% - Kjell Andersson Kjell Andersson via com
Slide 13: Calendar
QA Calendar November 20, 2025, Interim report Q3 February 18, 2026, Year-end report 2025 April 16, 2026, Annual Report 2025 IR contact ir@cincluspharma.com 13